Glycogen storage disease type II (also called Pompe disease or acid maltase deficiency) is a rare genetic disorder caused by a deficiency in the enzyme acid alpha-glucosidase (GAA), which is needed to break down glycogen, a stored form of sugar used for energy. It is the only glycogen storage disease with a defect in lysosomal metabolism, and was the first glycogen storage disease to be identified—in 1932. The build-up of glycogen causes progressive muscle weakness (myopathy) throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver and nervous system. Transmission is by autosomal recessive inheritance. Children have a 1 in 4 chance of inheriting the disease when both parents carry the abnormal gene. It is estimated to occur in about 1 in 40,000-300,000 births.

Variants

---

Pompe disease has three forms defined by age of onset and progression of symptoms:

Infantile, or early onset, is noticed shortly after birth. Symptoms include severe lack of muscle tone, weakness, and enlarged liver and heart. Mental function is not affected. Development appears normal for the first weeks or months but slowly declines as the disease progresses. Swallowing may become difficult and the tongue may protrude and become enlarged. Most children die from respiratory or cardiac complications before 2 years of age.

More on [ Glycogen storage disease type II ]

Glycogen Storage Disease Type II - Twitter Search

New insights into therapeutic options for Pompe disease: Glycogen storage disease type II or Pompe disease (GSD ... http://t.co/3BahQGpm
iubmbwiley (IUBMB@Wiley) Fri, 14 Oct 2011 15:19:13 -0000
New insights into therapeutic options for Pompe disease: Glycogen storage disease type II or Pompe disease (GSD ... http://t.co/3BahQGpm

Subscribe to Glycogen_Storage_Disease_Type_II RSS feed